指南与共识乳腺癌支持与姑息治疗

乳腺癌抗体药物偶联物不良反应管理指南(2025版)

[Guidelines for managing adverse reactions to antibody-drug conjugates in breast cancer (2025 edition)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

中国抗癌协会乳腺癌专业委员会与中国妇幼健康研究会乳腺癌防治研究专业委员会联合制定该指南,基于ADC在乳腺癌治疗的研究进展与国内外临床实践经验,针对ADC特有的不良反应谱,提供早期识别、定期评估、及时管理和随访监测的实践指导。

要点

  • ADC由抗体、细胞毒性载荷、连接子及偶联过程构成,不良反应独特且类别内安全谱异质。
  • 指南聚焦ADC相关不良反应或不良事件的早期识别、定期评估、及时管理与随访监测。
  • T-DM1与T-DXd显著延长HER2阳性患者无进展生存和总生存,正向前线探索。

核心结论

  • 指南为临床医护人员提供ADC相关不良反应或不良事件早期识别、定期评估、及时管理及随访监测的实践指导。

研究设计与样本

  • 由中国抗癌协会乳腺癌专业委员会和中国妇幼健康研究会乳腺癌防治研究专业委员会共同制定。
  • 依据ADC药物在乳腺癌治疗的研究进展并结合国内外临床实践经验制定。

主要发现

  • ADC将单克隆抗体的精准靶向性与有效载荷的细胞毒性药物强大杀伤力相结合,实现「精准递送、高效杀伤」。
  • ADC涉及抗体、细胞毒性制剂、连接子及偶联过程,导致不良反应独特且类别内安全谱异质。
  • 恩美曲妥珠单抗和德曲妥珠单抗显著延长HER2阳性患者的无进展生存时间和总生存时间。

临床怎么用

  • 临床医护人员应针对ADC相关不良反应或不良事件进行早期识别、定期评估、及时管理和随访监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer is the most common malignancy among women worldwide, with its incidence continuing to rise, posing a serious threat to women's health. In recent years, with the widespread adoption of molecular subtyping in diagnosis and treatment, breast cancer therapy has entered an era of individualized precision medicine. Early-stage breast cancer is primarily managed with surgery, combined with chemotherapy, radiotherapy, endocrine therapy, and targeted therapies (such as trastuzumab and pertuzumab), significantly improving cure rates. However, for recurrent or metastatic breast cancer, particularly refractory subtypes such as triple-negative and HER2-positive breast cancer, the efficacy of traditional treatments remains limited, and patients still face a poor prognosis. Antibody-drug conjugates (ADCs), as an innovative targeted therapy strategy, combine the precise targeting of monoclonal antibodies with the potent cytotoxicity of payload drugs, delivering cytotoxic agents directly to tumors through targeted chemotherapy, achieving "precision delivery and efficient killing". ADCs represent a relatively novel class of highly targeted anticancer biologics. In the field of breast cancer treatment, ADCs have made groundbreaking progress. Agents such as T-DM1 and T-DXd have significantly prolonged progression-free survival and overall survival in HER2-positive patients, providing critical treatment options for advanced-stage patients, markedly improving survival outcomes, and are now being explored in earlier lines of therapy, reshaping the treatment landscape of breast cancer. Although ADCs are generally well-tolerated, their unique structure-comprising antibodies, cytotoxic payloads, linkers, and conjugation processes-leads to distinct adverse effects and heterogeneous safety profiles within the class. Based on the latest research advances in ADC therapy for breast cancer and incorporating clinical experience from both domestic and international settings, the Breast Cancer Professional Committee of China Anti-Cancer Association, along with Breast Cancer Prevention and Treatment Research Professional Committee of Maternal and Child Health Research Society of China have jointly developed the "Guidelines for managing adverse reactions to antibody-drug conjugates in breast cancer (2025 edition)". This guideline aims to provide healthcare professionals with practical guidance on the early identification, regular assessment, timely management, and follow-up monitoring of ADC-related adverse reactions or events. 乳腺癌是全球女性最常见的恶性肿瘤,其发病率持续上升,严重威胁女性健康。近年来,随着分子分型诊疗模式的普及,乳腺癌治疗已进入个体化精准时代。早期乳腺癌以手术为主,结合化疗、放疗、内分泌治疗及靶向治疗(如曲妥珠单抗、帕妥珠单抗)等综合手段,显著提高了治愈率。然而,对于复发或转移性乳腺癌,尤其是三阴性及人表皮生长因子受体2(HER-2)阳性等难治性亚型,传统治疗手段疗效有限,患者仍面临预后不佳的挑战。抗体药物偶联物(ADC)作为一种创新的靶向治疗策略,将单克隆抗体的精准靶向性与有效载荷的细胞毒性药物的强大杀伤力相结合,通过靶向化疗的方式将细胞毒性药物释放至肿瘤,实现了“精准递送、高效杀伤”,是一类相对新颖的具有高度靶向性的抗癌生物制剂。ADC药物在乳腺癌治疗领域取得了突破性进展,如恩美曲妥珠单抗和德曲妥珠单抗等药物显著延长了HER-2阳性患者的无进展生存时间和总生存时间,为晚期患者提供了重要的治疗选择,显著改善了生存预后,并正在向更前线治疗探索,重塑着乳腺癌的治疗格局。虽然ADC总体上安全性良好,但由于其涉及抗体、细胞毒性制剂、连接子以及偶联过程,导致了ADC不良反应的独特性及其类别内安全谱的异质性。中国抗癌协会乳腺癌专业委员会和中国妇幼健康研究会乳腺癌防治研究专业委员会根据ADC药物在乳腺癌治疗的研究进展,结合国内外临床实践经验,共同制定了《乳腺癌抗体药物偶联物不良反应管理指南(2025版)》,旨在为临床医护人员提供ADC相关不良反应或不良事件的早期识别、定期评估、及时管理以及随访监测的实践指导。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Guidelines for managing adverse reactions to antibody-drug conjugates in breast cancer (2025 edition)]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 41539968. doi:10.3760/cma.j.cn112152-20251012-00502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。